GlassScriptPhysician profile
Armin Ronaghy
NPI 1275100638
$1,446.11
in general payments reported to CMS, 2019-2025
13 companies · $40.69 in 2025
The $40.69 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,150 · 2024: $255 · 2025: $40.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $243.68 | 2023-2024 | Saphnelo |
| Regeneron Healthcare Solutions, INC. | $239.80 | 2023 | Dupixent |
| Boston Scientific Corporation | $149.08 | 2023 | Watchman Access System |
| Genentech, INC. | $148.92 | 2023 | Evrysdi |
| Edwards Lifesciences Corporation | $148.51 | 2023 | Sapien 3 Ultra Resilia |
| Si-Bone, INC. | $143.57 | 2023 | |
| Janssen Biotech, INC. | $123.01 | 2023 | Simponi Aria |
| Ucb, INC. | $118.07 | 2024 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $40.69 | 2025 | Zoryve |
| Pierre Fabre Pharmaceuticals, INC. | $30.56 | 2023 | Hemangeol |
| Verrica Pharmaceuticals INC. | $24.81 | 2023 | Ycanth |
| Abbvie INC. | $21.17 | 2024 | |
| Nobelpharma America, LLC | $14.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armin Ronaghy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.